BioSpace

Tenaya’s share slump following the TN-201 data drop could be due to its “significantly lower” level of RNA expression in the Phase Ib/II trial than in preclinical models, according to William Blair analysts. #heartdisease #genetherapy #biospace https://hubs.li/Q03017Vv0

The vaccine maker previously revealed plans to slash R&D budget to conserve cash for product launches, but after a rough year of consistent share value decline, analysts remain skeptical. #research #pharma #biospace https://hubs.li/Q02_Yp5x0

Outlook Therapeutics, Inc. is among the latest companies to trim their workforces. Get the details on this and other staff cuts in our layoff tracker. #layoffs #biopharma #biospace https://hubs.li/Q02_Xd4R0

The Phase III win could help Regeneron and Bayer expand into retinal vein occlusion, a move that the partners need to help shore up sales of their Eylea franchise amid biosimilar encroachment. #pharma #biospace https://hubs.li/Q02_Wwbj0

The FDA on Monday handed out a pair of atopic dermatitis nods, one of which went to Galderma and its subcutaneous injection Nemluvio (nemolizumab-ilto), which is indicated for patients aged 12 years and above who have moderate-to-severe atopic dermatitis. #FDA #pharma #biospace https://hubs.li/Q02_Wc4z0

Both vibostolimab and favezelimab have had disappointing runs leading up to their termination, sustaining several late-stage failures. #cancertreatments #drugpipeline #pharma #biospace https://hubs.li/Q02_Wfmv0

The FDA cited issues with a manufacturing facility as the reason for the rejection. Johnson & Johnson is currently “working closely” with the regulator to resolve these problems. #FDA #pharma #biospace https://hubs.li/Q02_W3GK0

Businessman and entrepreneur Mark Cuban recently discussed leadership with Leadership Lab columnist Michael Pietrack. The three lessons that came out of that conversation start with one word: caring. #leadership #careers #biopharma #biospace https://hubs.li/Q02_WcsB0

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo Nordisk's GLP-1 drug but until now have declined to move forward with a more formal review. Two new studies have strengthened the link. #GLP-1 #ozempic #biospace https://hubs.li/Q02_NxHz0

Bristol Myers Squibb aims to generate around $1.5 billion in savings through 2025—a goal that it hopes to reach by lowering third-party expenditures, focusing only on key growth brands and cutting some 2,200 jobs by year-end. #pharma #biospace https://hubs.li/Q02_MCTN0